Evidence map›Paper›PMID 40821121›Full record

ReviewGenes & diseases2025

Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication.

Yulong Han, Binqiang Zhu, Shu Meng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. LGMNFrontiers in immunology · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yulong HanState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
Binqiang ZhuDepartment of Basic Science Research, Guangzhou National Laboratory, Guangzhou, Guangdong 510005, China.
Shu MengState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510120, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A hallmark feature of cancer is its capacity to induce the development of new blood vessels. Anti-angiogenic therapies are commonly employed to combat various types of cancer. Despite notable advancements in this field, limited efficacy and resistance remain critical challenges. While anti-angiogenic therapy primarily targets endothelial cells within the abnormal vasculature, the origins of tumor vascular endothelial cells in solid tumors remain a subject of ongoing debate. Unraveling the origins of these endothelial cells is crucial for developing more effective strategies to combat tumor angiogenesis. This review summarizes the latest findings on the origins of endothelial cells in tumor angiogenesis and explores the progress, limitations, and future directions of anti-angiogenic therapy.

Indexed as

AngiogenesisAnti-angiogenic therapyOrigins of endothelial cellsTumor angiogenesisTumor endothelial cells

Identifiers

PMID40821121
PMCPMC12357263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.